Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Projects and Technology
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Projects and Technology
    • Veterinary Medicine
      • Paccal Vet – Dog
      • Paccal Vet – Cat
    • Project Portfolio – Human Pharmaceuticals
      • Cantrixil
      • Apealea
    • XR Drug Delivery Platform
      • Advantages
      • Patent Protection
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

Regulatory Releases
  • Press Releases
  • All releases
2015
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Regulatory
November 30, 2015

Publication of change in the total number of shares and votes in Oasmia

Regulatory
October 23, 2015

Nexttobe extends loan to Oasmia

Regulatory
September 5, 2015

Interim report for the period May – July 2014

Regulatory
August 31, 2015

Notice convening the Annual General Meeting of Oasmia Pharmaceutical AB

Regulatory
May 29, 2015

Communiqué from Oasmia’s Extraordinary General Meeting 2015

Regulatory
May 7, 2015

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB (publ)

Regulatory
April 20, 2015

Oasmia’s lead cancer product Paclical® receives market approval in the Russian Federation

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact

Now enrolling:

Paccal Vet hemangiosarcoma trial

A clinical study for dogs with splenic hemangiosarcoma

Learn more and take survey to see if you may qualify

 

Take me there
Vivesto logo
  • About Us
  • Projects and Technology
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com